Articles by Elena Garralda

Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed 

Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world

Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care

Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches

Many studies presented at ESMO Congress 2022 show the potential of artificial intelligence to enhance personalised oncology

Recent evidence suggests a role of the microbiome in cancer pathogenesis and as a potential therapeutic target, but it is still early days

The new FDA guidance could be an important step toward necessary change to give adequate representation of older adults in cancer clinical trials

Thanks to our deeper understanding of the underlying biology and molecular mechanisms that govern cancer, we are gaining important ground in tackling the myriad mediators of this disease. 

As we all return back to practice after the busy and buzzing ESMO Congress 2021, myriad clinical questions have been addressed and debated, with many even solved. But, there is still much work to be done if we are to collectively deliver on the promise of precision medicine in oncology, and in so doing, continue to improve outcomes for our patients.

Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.